Small tumors, big decisions: Rethinking resection and ablation in early hepatocellular carcinoma
World Journal of Gastroenterology · 07.08.2026 · 32 (29)
DOI: 10.3748/wjg.116653 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 07.08.2026. Verfasst von Marcello Maestri und 1 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
The management of small hepatocellular carcinoma (HCC) remains a matter of active debate. The recent study by Lei et al provides valuable evidence comparing laparoscopic hepatectomy (LH) and radiofrequency ablation (RFA) in patients with tumors ≤ 5 cm. In this retrospective analysis of 254 cases, LH achieved superior three-year overall and disease-free survival compared with RFA (85% vs 66% and 64% vs 45%, respectively), despite longer operative times and higher postoperative morbidity. These findings reinforce the oncologic advantage of anatomical resection in removing microscopic disease beyond radiologically visible margins. The biological rationale is compelling: While RFA induces local necrosis within a constrained ablation zone, LH allows complete excision of the tumor and surrounding parenchyma, thereby addressing microvascular invasion and satellite nodules that frequently accompany early HCC. Nonetheless, RFA retains an essential role for patients with limited hepatic reserve or comorbidities precluding surgery, offering a safe and repeatable alternative with minimal physiological impact. The results of Lei et al also prompt reappraisal of the Barcelona Clinic Liver Cancer framework, which may inadequately reflect advances in laparoscopic and ablative technologies. Modern treatment selection should move beyond stage-based algorithms toward individualized decision-making integrating liver function, tumor biology, and patient frailty. In appropriately selected candidates, LH should remain the reference curative option, while RFA continues to provide meaningful benefit in high-risk or inoperable patients. Together, they represent complementary strategies within the evolving continuum of curative therapies for small HCC.
Zitieren
APA
Maestri, M., & Cicerone, O. (2026). Small tumors, big decisions: Rethinking resection and ablation in early hepatocellular carcinoma. World Journal of Gastroenterology, 32(29). https://doi.org/10.3748/wjg.116653
Vancouver
Maestri M, Cicerone O. Small tumors, big decisions: Rethinking resection and ablation in early hepatocellular carcinoma. World Journal of Gastroenterology. 2026;32(29). doi:10.3748/wjg.116653
BibTeX
@article{Maestri2026,
author = {Maestri, Marcello and Cicerone, Ottavia},
title = {Small tumors, big decisions: Rethinking resection and ablation in early hepatocellular carcinoma},
journal = {World Journal of Gastroenterology},
year = {2026},
volume = {32},
number = {29},
doi = {10.3748/wjg.116653}
}
EUVIMED